BALA CYNWYD, Pa.--(BUSINESS WIRE)--June 30, 2006--Duska Therapeutics, Inc. (OTCBB:DSKT - News), a biopharmaceutical company focused on the development of diagnostic and therapeutic products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that Dr. John Kapoor has resigned from the Board of Directors (Board). The Board has accepted Dr. Kapoor’s recommendation and appointed his assistant Mr. Michael L. Babich as director of the Company.
